NEW YORK ( TheStreet) - HCA Holdings ( HCA), Thermo Fisher ( TMO), Covidien PLC ( COV), Mednax ( MD), Bio-Rad Labs ( BIO), Pharmasset ( VRUS), Unitedhealth Group ( UNH), Sironal Dental ( SIRO), Illumina ( IIMN) and United Therapeutics Corporation ( UTHR) have an average buying rating of 85%, according to a Bloomberg consensus. The S&P Global Healthcare Sector ETF ( IXJ), an indicator for the performance of health care stocks outperformed the S&P 500 INDEX by about 600 basis points in the last seven months. The S&P Healthcare Sector ETF moved up 6.5%, while S&P Index was more or less flat during this period. The relative low volatility of these stocks compared to broader indices augurs well for the sector, given the current market scenario. We have identified 10 health care stocks which, according to analysts, could outperform their peers and broader market indices. These stocks have upside potential of 28% to 47% with a mean upside value of 33%. By contrast, pharma giants Johnson & Johnson ( JNJ), Abbott Laboratories ( ABT), Bristol Myers Squibb ( BMY) and Eli Lilly ( LLY) have upsides ranging from -1% to 16%, according to analysts' estimates. These 10 stocks are listed in terms of buy ratings, great to greatest.